Jaafar Bennouna Selected Research

Neoplasm Antigens (Tumor Antigens)

11/2018	[Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].
3/2012	Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jaafar Bennouna Research Topics

Disease

57	Neoplasms (Cancer) 04/2024 - 01/2002
41	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 03/2008
41	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 04/2002
19	Disease Progression 01/2022 - 05/2010
11	Adenocarcinoma 12/2020 - 05/2009
10	Lung Neoplasms (Lung Cancer) 04/2024 - 03/2012
8	Fatigue 06/2023 - 05/2010
7	Colonic Neoplasms (Colon Cancer) 01/2022 - 05/2016
7	Asthenia 01/2021 - 09/2011
6	Stomatitis 06/2023 - 10/2012
6	Exanthema (Rash) 06/2023 - 09/2012
6	Neutropenia 01/2021 - 05/2010
6	Pancreatic Neoplasms (Pancreatic Cancer) 01/2017 - 05/2009
5	Diarrhea 06/2023 - 05/2010
5	Nausea 06/2023 - 09/2007
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 08/2017
5	Carcinoma (Carcinomatosis) 04/2021 - 09/2005
4	Neoplasm Metastasis (Metastasis) 10/2023 - 09/2005
4	Adenocarcinoma of Lung 06/2023 - 09/2013
4	Esophageal Neoplasms (Esophageal Cancer) 07/2021 - 04/2019
4	Malignant Mesothelioma 01/2020 - 01/2019
4	Hypertension (High Blood Pressure) 01/2020 - 03/2011
4	Breast Neoplasms (Breast Cancer) 12/2019 - 03/2008
4	Vomiting 12/2018 - 09/2007
4	Febrile Neutropenia 12/2018 - 05/2010
4	Abdominal Pain (Pain, Abdominal) 10/2011 - 05/2010
3	Dyspnea (Shortness of Breath) 12/2023 - 09/2013
3	Microsatellite Instability 12/2023 - 11/2020
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2023 - 04/2015
3	Pain (Aches) 06/2023 - 09/2013
3	Acne Vulgaris 06/2023 - 09/2013
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2020 - 11/2008
3	Thrombocytopenia (Thrombopenia) 12/2018 - 05/2010
2	Brain Neoplasms (Brain Tumor) 10/2023 - 01/2018
2	Cough 06/2023 - 09/2013
2	Peripheral Nervous System Diseases (PNS Diseases) 01/2023 - 05/2010
2	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2021 - 11/2014
2	Mesothelioma 01/2020 - 01/2019
2	Edema (Dropsy) 01/2020 - 05/2010
2	Melanoma (Melanoma, Malignant) 01/2020 - 01/2002
2	Hand-Foot Syndrome 10/2011 - 01/2009
2	Prostatic Neoplasms (Prostate Cancer) 02/2006 - 09/2003

Drug/Important Bio-Agent (IBA)

17	Bevacizumab (Avastin)FDA Link 01/2022 - 05/2009
15	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2023 - 05/2008
15	Fluorouracil (Carac)FDA LinkGeneric 01/2022 - 01/2007
14	PlatinumIBA 01/2020 - 09/2007
13	Cisplatin (Platino)FDA LinkGeneric 06/2023 - 09/2011
12	pembrolizumabIBA 12/2023 - 01/2018
12	Docetaxel (Taxotere)FDA Link 01/2022 - 05/2010
11	Irinotecan (Camptosar)FDA LinkGeneric 12/2020 - 04/2002
10	AfatinibIBA 06/2023 - 09/2013
10	Leucovorin (Folinic Acid)FDA Link 01/2020 - 04/2002
8	Tyrosine Kinase InhibitorsIBA 01/2020 - 06/2014
8	Gemcitabine FDA Link 12/2018 - 05/2009
7	Immune Checkpoint InhibitorsIBA 12/2023 - 01/2020
6	Proteins (Proteins, Gene)FDA Link 04/2024 - 01/2002
6	Pemetrexed (MTA)FDA Link 06/2023 - 09/2013
6	ErbB Receptors (EGF Receptor)IBA 01/2022 - 06/2014
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 03/2011
5	Cetuximab (Erbitux)FDA Link 01/2022 - 05/2012
5	Biomarkers (Surrogate Marker)IBA 10/2021 - 01/2017
5	vinflunineIBA 06/2012 - 10/2005
4	AntibodiesIBA 10/2021 - 01/2002
4	B7-H1 AntigenIBA 07/2021 - 01/2019
4	130-nm albumin-bound paclitaxelIBA 04/2020 - 01/2017
3	NivolumabIBA 01/2023 - 11/2020
3	durvalumabIBA 01/2023 - 01/2020
3	IpilimumabIBA 01/2023 - 11/2020
3	avelumabIBA 04/2022 - 01/2019
3	chemotactic factor inactivatorIBA 01/2022 - 01/2018
3	Protons (Proton)IBA 08/2021 - 08/2019
3	folfirinoxIBA 01/2019 - 05/2011
3	Capecitabine (Xeloda)FDA Link 01/2018 - 02/2011
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2017 - 05/2009
3	Vinorelbine (Navelbine)FDA LinkGeneric 01/2016 - 10/2011
2	Carcinoembryonic AntigenIBA 01/2023 - 01/2021
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022 - 03/2011
2	Interferon Type IIBA 01/2021 - 01/2020
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2020 - 09/2011
2	Axitinib (AG 013736)IBA 01/2020 - 03/2011
2	LigandsIBA 01/2019 - 10/2005
2	Neoplasm Antigens (Tumor Antigens)IBA 11/2018 - 03/2012
2	nintedanibIBA 01/2017 - 11/2015
2	AntigensIBA 01/2017 - 03/2002
2	XELOXIBA 02/2011 - 05/2008
2	Interleukin-2 (IL2)IBA 10/2010 - 11/2008
2	CeramidesIBA 02/2006 - 09/2003
2	AndrogensIBA 02/2006 - 09/2003
2	Peptides (Polypeptides)IBA 03/2002 - 01/2002
1	canakinumab FDA Link 12/2023

Therapy/Procedure

55	Drug Therapy (Chemotherapy) 04/2024 - 04/2002
25	Therapeutics 04/2024 - 09/2003
6	Immunotherapy 11/2023 - 10/2005
5	Adjuvant Chemotherapy 01/2019 - 04/2002
3	Precision Medicine 01/2022 - 01/2020
3	Proton Therapy 08/2021 - 08/2019
3	Radiotherapy 11/2014 - 09/2011
2	Duration of Therapy 10/2021 - 01/2018
2	Chemoradiotherapy 04/2021 - 11/2014
2	Induction Chemotherapy 01/2020 - 01/2018